The PBAC’s Drug Utilisation Sub-Committee (DUSC) has determined that usage of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) for stage IV adenocarcinoma of the pancreas is lower than originally predicted. The review of prescription data from November 2014 to March 2017 found 3,284 patients were supplied the drug since it was PBS-listed for first line treatment of locally advanced, ...
PBS review finds low use of pancreatic cancer drug
By Mardi Chapman
6 Mar 2018